Hemogenyx Pharmaceuticals PLC (LSE:HEMO) — Market Cap & Net Worth
Market Cap & Net Worth: Hemogenyx Pharmaceuticals PLC (HEMO)
Hemogenyx Pharmaceuticals PLC (LSE:HEMO) has a market capitalization of $306.59K (GBX2.52 Billion) as of September 24, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31232 globally and #992 in its home market, demonstrating a 3.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemogenyx Pharmaceuticals PLC's stock price GBX470.00 by its total outstanding shares 5361267 (5.36 Million). Also see Hemogenyx Pharmaceuticals PLC asset portfolio for a full breakdown of the balance sheet.
Hemogenyx Pharmaceuticals PLC Market Cap History: 2015 to 2026
Hemogenyx Pharmaceuticals PLC's market capitalization history from 2015 to 2026. Data shows growth from $2.45K to $306.59K (56.91% CAGR). Also see cash flow conversion of Hemogenyx Pharmaceuticals PLC for how efficiently the company converts equity into cash flow.
Hemogenyx Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemogenyx Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Hemogenyx Pharmaceuticals PLC share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.36x
Hemogenyx Pharmaceuticals PLC's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.45K | $6.85K | -$180.88K | 0.36x | N/A |
Competitor Companies of HEMO by Market Capitalization
Companies near Hemogenyx Pharmaceuticals PLC in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Hemogenyx Pharmaceuticals PLC to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hemogenyx Pharmaceuticals PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Hemogenyx Pharmaceuticals PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Hemogenyx Pharmaceuticals PLC's market cap moved from $2.45K to $ 306.59K, with a yearly change of 56.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX306.59K | -17.83% |
| 2025 | GBX373.12K | +41.23% |
| 2024 | GBX264.19K | +17508.70% |
| 2023 | GBX1.50K | +73.58% |
| 2022 | GBX864.31 | -23.19% |
| 2021 | GBX1.13K | -82.12% |
| 2020 | GBX6.29K | +394.87% |
| 2019 | GBX1.27K | -7.14% |
| 2018 | GBX1.37K | -16.00% |
| 2017 | GBX1.63K | -33.33% |
| 2015 | GBX2.45K | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Hemogenyx Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $306.59K USD |
| MoneyControl | $306.59K USD |
| MarketWatch | $306.59K USD |
| marketcap.company | $306.59K USD |
| Reuters | $306.59K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more